190 related articles for article (PubMed ID: 35201674)
1. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
[TBL] [Abstract][Full Text] [Related]
2. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
3. Early onset of efficacy with erenumab in patients with episodic and chronic migraine.
Schwedt T; Reuter U; Tepper S; Ashina M; Kudrow D; Broessner G; Boudreau GP; McAllister P; Vu T; Zhang F; Cheng S; Picard H; Wen S; Kahn J; Klatt J; Mikol D
J Headache Pain; 2018 Oct; 19(1):92. PubMed ID: 30276500
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
5. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
8. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
[TBL] [Abstract][Full Text] [Related]
9. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
11. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a
Lipton RB; Tepper SJ; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Zhang F; Rippon GA; Cheng S; Mikol DD
Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
13. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
14. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
17. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
18. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
[TBL] [Abstract][Full Text] [Related]
19. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
20. The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN).
Filippi M; Messina R; Bartezaghi M; Cetta I; Colombo B; Grazzi L; Martinelli D; Ornello R; Pichiecchio A; Raimondi D; Russo A; Sacco S; Splendiani A; Tassorelli C; Turrini R; Valsasina P; Rocca MA;
J Neurol; 2023 Nov; 270(11):5600-5612. PubMed ID: 37550498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]